Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Virtual Booth

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ssr 125543, Ssr125543, Ssr-125543, 752253-39-7, Nbi-74788, Crinecerfont [usan]

Molecular Formula

C₂₇H₂₈ClFN₂OS

Molecular Weight

483.0 g/mol

InChI Key

IEAKXXNRGSLYTQ-DEOSSOPVSA-N

FDA UNII

MFT24BX55I

1 2D Structure

Crinecerfont

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine

2.1.2 InChI

InChI=1S/C27H28ClFN2OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H2,2-5H3/t24-/m0/s1

2.1.3 InChI Key

IEAKXXNRGSLYTQ-DEOSSOPVSA-N

2.1.4 Canonical SMILES

CC1=C(C=C(C=C1)C(CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F

2.1.5 Isomeric SMILES

CC1=C(C=C(C=C1)[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F

2.2 Other Identifiers

2.2.1 UNII

MFT24BX55I

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

2. Nbi 74788

3. Nbi-74788

2.3.2 Depositor-Supplied Synonyms

1. Ssr 125543

2. Ssr125543

3. Ssr-125543

4. 752253-39-7

5. Nbi-74788

6. Crinecerfont [usan]

7. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

8. Mft24bx55i

9. 06-rori

10. Chembl291657

11. Chebi:34969

12. Ssr125543a

13. 752253-39-7 (free Base)

14. Chembl1628268

15. (s)-4-(2-chloro-4-methoxy-5-methylphenyl)-n-(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-(prop-2-yn-1-yl)thiazol-2-amine

16. Sr-125543a

17. Crinecerfont [inn]

18. Unii-mft24bx55i

19. Gtpl3533

20. Schembl5453205

21. Dtxsid10996687

22. Ssr-125543a

23. Zinc1550164

24. Bdbm50144192

25. Bdbm50348828

26. Pdsp1_000883

27. Pdsp2_000869

28. Who 10958

29. Ncgc00386642-01

30. Hy-106203

31. Cs-0025238

32. Q27088874

33. [4-(4-bromo-phenyl)-5,6-dimethyl-pyrimidin-2-yl]-dicyclopropylmethyl-propyl-amine

34. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-((1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-n-2-propynyl-

35. 2-thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-2-propyn-1-yl

36. 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-(prop-2-yn-1-yl)-1,3-thiazol-2-amine

2.4 Create Date

2005-10-11

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₂₈ClFN₂OS
Molecular Weight	483.0 g/mol
XLogP3	8
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	8
Exact Mass	482.1594906 g/mol
Monoisotopic Mass	482.1594906 g/mol
Topological Polar Surface Area	53.6 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	699
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of atypical haemolytic uremic syndrome, Treatment of paroxysmal nocturnal haemoglobinuria

Treatment of congenital adrenal hyperplasia

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Crinecerfont manufacturers, exporters & distributors on PharmaCompass

Crinecerfont

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?